Bausch takes hit in Xifaxan patent feud, potentially paving the way for Norwich's IBS-D generic

Bausch Health, after waylaying other copycats of its irritable bowel syndrome diarrhea (IBS-D) drug Xifaxan, has been dealt a blow in court. The court order potentially creates an opening for Norwich Pharmaceuticals’ proposed generic to squeeze its way onto the market.